/
AKTX
$9.51-$0.18 (-1.86%)live
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Market cap
$16.9M
2M shares
52-week range
$3.02 – $49.60
14% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
ADRC
Price (6 mo)
Loading chart…
Change$-1374.49
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | $35.8K | $19.2K | $0 | $0 | $0 | $0 | $0 | $0 |
| Gross profit | −$35.8K | −$19.2K | $0 | $0 | $0 | $0 | $0 | $0 |
| Gross margin | — | — | — | — | — | — | — | — |
| R&D | $15.6M | $16.6M | $12.2M | $9.1M | $9.6M | $8.0M | $7.0M | $2.8M |
| Operating income | −$20.0M | −$24.9M | −$18.0M | −$17.2M | −$23.1M | −$16.8M | −$21.6M | −$17.3M |
| EBITDA | −$16.4M | −$24.7M | −$18.0M | −$17.4M | −$17.7M | −$10.0M | −$19.5M | −$17.4M |
| Net income | −$19.9M | −$16.8M | −$17.1M | −$17.4M | −$17.7M | −$10.0M | −$19.8M | −$17.3M |
| Net margin | — | — | — | — | — | — | — | — |
| EPS (diluted) | -2129600.00 | -1472000.00 | -896000.00 | -649600.00 | -455200.00 | -163200.00 | -132800.00 | -20800.00 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $10M | $-5.77 | $-5.77–$-5.77 | 2 |
| 2027 | $0 | $-4.68 | $-4.68–$-4.68 | 2 |
| 2028 | $0 | $-6.27 | $-6.27–$-6.27 | 2 |
| 2029 | $0 | $-7.24 | $-7.24–$-7.24 | 1 |
Forward consensus · source: Financial Modeling Prep
DCF fair valuemodel estimate
Intrinsic value
$3.26
Price
$9.51
Implied downside
-66%
Peer comparison
Akari Therapeutics plc ADR (0.01 USD)
Akari Therapeutics PLC is an oncology company developing next-generation antibody-drug conjugates (ADCs) built around novel, proprietary payloads utilizing powerful biology to attack cancer. Its payload, PH1, targets RNA splicing by modulating the spliceosome, a complex machinery in the cell that converts pre-RNA into spliced RNA for translation into vital proteins for cell survival and growth. Its product pipeline is AKTX-101, which targets the Trop2 receptor on cancer cells and, with a proprietary linker, enables it to deliver its novel PH1 payload directly into the tumor with minimal off-target effects. and AKTX-102, an ADC candidate targeting CEACAM5 (Carcinoembryonic Antigen-related Cell Adhesion Molecule-5), a well-validated tumor antigen expressed across multiple solid tumors.
www.akaritx.com- Employees
- 5
- IPO / List date
- Dec 7, 2012
- HQ
- TAMPA, FL
Held by traders on TradeandTell
No one on the platform currently holds AKTX.
Super investors & insiders
Institutions holding (13F)
No tracked institution reports a position in AKTX as of their last filing.
Insider activity (SEC Form 4)
Stock splits
| Execution date | Ratio |
|---|---|
| 2026-03-31 | 1-for-40reverse |
| 2023-08-17 | 1-for-20reverse |
| 2015-09-17 | 1-for-10reverse |
Recent trades on TradeandTell
No one on the platform has traded AKTX yet.
